ASCENT Study: Impact of Sacituzumab Govitecan on Metastatic TNBC
Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.
Metastatic Triple Negative Breast Cancer Overcoming Challenges Diagnosis Treatment Sacituzumab Govitecan Triple Negative Breast Cancer Second Line Options
Source: curetoday.com